reports
- GlobalData Department
Cascadian Therapeutics Inc (CASC) - Pharmaceuticals & Healthcare - Dea...
Summary Cascadian Therapeutics Inc (Cascadian), formerly Oncothyreon Inc is a clinical-stage biotechnology company that develops therapeutic products for the treatment of cancer. The company’s lead clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule HER2 inhibitor which is intended for the treatment of HER2-positive (HER2+) metastatic breast cancer. It also develops preclinical product candidates in oncology through its Chk1 kinase inhibitor and pr...
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of C...
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Cascadian Therapeutics, Inc. (NASDAQ GS: CASC)? Did you purchase any of your shares prior to January 31, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Compan...
CASCADIAN THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A....
WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Cascadian Therapeutics, Inc. (NASDAQ GS: CASC)? Did you purchase any of your shares prior to January 31, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Compan...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...
NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Cascadian Therapeutics, Inc. (“Cascadian Therapeutics” or the “Company”) (NASDAQ: CASC) stock prior to January 31, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Cascadian Therapeutics to Seattle Genetics, Inc. (NASDAQ: SGEN) for $10.00 per share. To learn more about the action and your rights, go to: ...
A director sold 23,000 shares at 4.240USD and
A director at Cascadian Therapeutics Inc sold 23,000 shares at 4.240USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.